OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Comparative Effectiveness Research is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis	49
Journal of Comparative Effectiveness Research : 2022 year in review	46
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy	38
Access in all areas? A round-up of developments in market access and health technology assessment: part 10	36
Engaging veterans in the research process: a practical guide	31
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary	30
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database	27
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis	26
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis	26
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis	25
Ataluren for the treatment of people living with nonsense mutation Duchenne muscular dystrophy: a plain language summary of Study 041	25
Corrigendum	22
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea	22
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies	21
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis	20
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20	18
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study	17
Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases	17
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims	17
Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review	16
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience	16
Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis	15
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?	15
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity	15
Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis	15

Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies	13
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA	13
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer	12
Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab	12
Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD	12
A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis	11
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China	11
Corrigendum	11
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations	11
Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China	11
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer	11
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada	11
Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients	11
Access in all areas? A round-up of developments in market access and health technology assessment: part 11	11
Cost–effectiveness of lung cancer screening with volume computed tomography in Portugal	11
Comparison of two-stage methods for count data in Mendelian randomization: a simulation study	10
Acceptability of external control-arm use in nononcology health technology assessment submissions	10
Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol	10
Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol	10
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	10
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	10
Impact of lymph node dissection on overall survival and cancer-specific survival in elderly patients with early-stage non-small cell lung cancer: a SEER database analysis	10
Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practic	10
The triple win – implementation science benefits patients, healthcare systems and industry alike	10
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors	9
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer	9
Rivaroxaban versus low-molecular-weight heparins for short- and long-term prognosis in patients with deep vein thrombosis after spontaneous intracranial hemorrhage	9
Impact of COVID-19 on chronic pain structures: data from French national survey	9
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies	9
Characterization of medical device randomized controlled trials with adaptive designs	9
COVID-19 clinical trials: who is likely to participate and why?	9
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care	9
Comparison of Enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study	9
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma	9
Tr14 gel for the treatment of acute ankle sprains: a plain language summary of the TRAUMED trial	9
Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome	9
Quality in qualitative evidence: new best practice principles from NICE’s real-world evidence framework	8
Access in all areas? A round up of developments in market access and health technology assessment: part 1	8
An impact evaluation of an education bundle for patients at risk of developing venous thromboembolism	8
The effects of Pilates on pain, functionality, quality of life, flexibility and endurance in lumbar disc herniation	8
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10	8
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	7
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison	7
Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization	7
Navigating adalimumab biosimilars: an expert opinion	7
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary	7
A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study	7
Composite endpoints in health technology assessment: Part 1 – an illustration of best modeling practice	7
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers	7
Corrigendum	7

Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US	7
Use of transportability methods for real-world evidence generation: a review of current applications	7
The inaugural HEMA report: a missed opportunity for comprehensive value assessment	7
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma	7
Treatment burden and healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps who did or did not undergo functional endoscopic sinus surgery: a US real-world retrospec	7
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma	7
Expanding the learning health system model to be health literate	7
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD	7
The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives	6
In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database	6
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	6
Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses	6
Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Mexico: a systematic review	6
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation	6
Cost-effectiveness modeling of mortality risk reduction comparing two fixed-dose combination triple therapies in moderate-to-very severe chronic obstructive pulmonary disease	6
A value-based budget impact model for dronedarone compared with other rhythm control strategies	6
Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus	6
QDOT MICRO™ versus THERMOCOOL ^® SMARTTOUCH™ and THERMOCOOL SMARTTOUCH ^® Surround Flow in radiofrequency ablation of paroxysmal atr	6
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges	6
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US	6
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant	6
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China	6
Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity	6
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions	6
Clinical and economic burden among older adults with acromegaly in the United States	6
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	6
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	6
Treatment goals for rheumatoid arthritis: patient engagement and goal collection	6
Real-world clinical outcomes of patients with localized prostate cancer treated with radical prostatectomy in SEER-Medicare	5
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs	5
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15	5
An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study)	5
Val (EU) xit: do we need an international ISPOR value flower?	5
Advancing real-world evidence harmonization: lessons from the UK, EMA and global policy frameworks	5
Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA	5
Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims	5
A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms	5
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants	5
Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial	5
How pharma can amplify product value with implementation science	5
COVID-19 complications in males and females: recent developments	5
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study	5
Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study	5
The effects of exercises with a Pilates ball on balance, reaction time and dual-task performance of kindergarten children	5
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data	5
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis	5
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis	5
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	5
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis	5
The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada	5
Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data	5
Impact analysis of expanded access to ketamine for treatment-resistant depression	5
Visualizing the target estimand in comparative effectiveness studies with multiple treatments	5
Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy	5
Resource utilization and economic outcomes following repetitive transcranial magnetic stimulation for treatment-resistant depression: a retrospective observational analysis	5
The need to consider market access for pharmaceutical investment decisions: a primer	5
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting	5